Introduction
This summary of the 2007 ERA-EDTA Registry Report includes data on renal replacement therapy (RRT) from 49 national and regional registries in 28 countries in Europe and bordering the Mediterranean Sea ( Figure 1 ). Data sets with individual patient data for analysis were received from 34 registries, whereas 17 registries contributed data only in aggregated form. For both types of registries, we present incidence and prevalence data as well as transplant rates. Survival analysis used the data from countries and regions that provided individual patient records. More detailed data than those presented in this paper can be found in the 2007 ERA-EDTA Registry Report [1] that is also available on www.era-edta-reg.org.
The incidence of RRT for ESRD across Europe
In 2007, the overall incidence rate of RRT for end-stage renal disease (ESRD) among all registries reporting to the ERA-EDTA Registry was 116 per million population (pmp). Figure 2 shows that the highest incidence rates at Day 1 were reported by Turkey (231 pmp), Portugal (227 pmp) and Israel (193 pmp), whereas incidence rates below 100 pmp were reported by Ukraine (20 pmp), Russia (31 pmp), Montenegro (32 pmp), Iceland (81 pmp), Latvia (86 pmp), Romania (90 pmp), Finland (92 pmp) and FYR of Macedonia (92 pmp). The mean age at the start of RRT ranged from 43 years (Ukraine) to 69 years (Belgium) (Figure 2 ). Table 1 shows the incidence rate of RRT over the period [2003] [2004] [2005] [2006] [2007] for countries and regions providing individual patient data, adjusted for age and gender distribution.
For the age group 0-19 years at the start of RRT, data were available for a limited number of registries including those of Austria, Denmark, Finland, Greece, Iceland, Norway, Romania, Spain (Andalusia), Spain (Aragon), Spain Denmark  133  131  119  117  136  F i n l a n d  9 3  9 4  9 2  8 3  8 5  Greece  168  177  171  172  164  Iceland  83  87  81  79  84  Italy, Calabria  130  137  127  121  132  Norway  97  102  101  101  113  Spain, Andalusia  137  138  141  139  125  Spain, Aragon  87  114  119  93  113  Spain, Asturias  108  132  101  102  103  Spain, Basque country  128  112  107  99  98  Spain, Cantabria  126  135  142  115  99  Spain, Castile and  Leon   98  100  91  101 an overview of paediatric RRT data collected from those registries, please visit www.espn-reg.org. Table 3 shows the incidence rate of RRT by age group, for countries and regions providing individual patient data. For the highest age groups, the highest incidence rates were reported from Belgium and Greece, whereas Finland and Romania belong to the countries reporting the lowest incidence rates.
The incidence rates of RRT for ESRD due to diabetes mellitus were highest in Israel (81 pmp), Turkey (64 pmp), and Slovakia (60 pmp), whereas the highest incidence rates of RRT for ESRD due to hypertension/renal vascular disease were reported from Turkey (58 pmp), and Belgium (52 pmp) ( Table 4 ).
The prevalence of RRT for ESRD across Europe
The overall prevalence among all registries reporting to the ERA-EDTA Registry was 662 pmp. Figure 3 shows that the prevalence of RRT pmp at 31 December 2007 was highest in Portugal (1372 pmp), Belgium (French-speaking) (1109 pmp) and Spain (Catalonia) (1100 pmp). The lowest prevalence was reported by Ukraine (85 pmp) and Russia (146 pmp). The mean age at 31 December 2007 ranged from 44 years (Russia and Ukraine) to 64 years (Belgium, Dutch speaking) for registries providing data both on dialysis and transplant patients (Figure 3 ). Table 5 shows the overall prevalence of RRT, adjusted for age and gender distribution.
Only a limited number of registries provided complete data for prevalent patients in the age group 0-19 years in 2007, including those of Austria, Denmark, Finland, Greece, Iceland, Norway, Romania, Spain (Andalusia), Spain (Aragon), Spain (Basque country), Spain (Catalonia), Spain (Valencian region), Sweden, The Netherlands and United Kingdom (Scotland). The prevalence for age group 0-19 years is presented in Table 6 . Table 7 shows that for the highest age groups, the highest prevalence was reported by Belgium, Greece, Italy, and several Spanish registries. Conflict of interest statement. None declared.
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Appendix: statistical methods
To Table 8 Data presented include the survival of incident patients on RRT and of patients receiving a first transplant be- For the analysis of patient survival on RRT, the day at the start of RRT was taken as the starting point and the event studied was death. Censored observations were recovery of renal function, loss to follow-up and end of follow-up time. For the analysis of patient survival on dialysis, the first day on dialysis was the starting point, the event was death and reasons for censoring were recovery of renal function, loss to follow-up, end of follow-up time and renal transplantation.
For the analysis of patient and graft survival after transplantation, the date of the first renal transplantation was defined as the first day of follow-up.
For the patient survival after transplantation, the event studied was death and for the graft survival the events were graft failure and death. Reasons for censoring were loss to follow-up and end of follow-up time.
To Figure 5 For the analyses of patient survival on dialysis the starting point was Day 91 on dialysis. Analyses were adjusted for the fixed values of age (60 years), gender (60% men) and primary renal disease (20% diabetes mellitus, 17% hypertension/renal vascular disease, 15% glomerulonephritis and 48% other cause). 
